Outlook Therapeutics Engages in Insightful Virtual Discussion
In a recent virtual event, Dr. Jennifer Kissner, Senior Vice President of Clinical Development at Outlook Therapeutics, shared vital insights regarding the findings from the 12-week safety and efficacy results of the NORSE EIGHT clinical trial. This engagement is a part of Outlook’s initiative to keep stakeholders informed and to clarify what these developments mean for the future of ophthalmic treatments.
Understanding the NORSE EIGHT Findings
During the segment, Dr. Kissner elaborated on the outcomes of NORSE EIGHT, which is pivotal in evaluating ONS-5010, an investigational ophthalmic formulation targeting wet age-related macular degeneration (wet AMD). The results from this trial are crucial as they pave the way for a Biologics License Application (BLA) resubmission anticipated in early 2025.
Importance of the NORSE EIGHT Trial
This particular clinical investigation is significant, being the second of two well-controlled trials aimed at establishing the safety and effectiveness of ONS-5010. The insights gathered here are expected to support the application process, enabling more patients to potentially benefit from innovative treatment options in the near future.
What’s Next for Outlook Therapeutics?
Following the discussions in the virtual segment, Outlook Therapeutics is preparing for the commercial launch of LYTENAVA™ (bevacizumab gamma) across the European Union (EU) and the UK. This formulation has already received regulatory approval, marking a significant achievement for the company as it pushes forward in bringing this treatment to market.
LYTENAVA™: A Promising Treatment
LYTENAVA™ is recognized as the first authorized ophthalmic formulation of bevacizumab, designed specifically for treating retina diseases, including wet AMD. Its anticipated launch in the EU and UK aims to provide patients with safer and more effective options when dealing with retina-related illnesses.
Current Research and Future Prospects
In the United States, while ONS-5010 continues to be investigated in an ongoing study, the company is optimistic about the resubmission of its BLA to the FDA. Successful clinical trial outcomes might make history if ONS-5010 is approved, becoming the first ophthalmic version of bevacizumab indicated for retinal diseases.
About Outlook Therapeutics
Outlook Therapeutics, Inc. is on the forefront of biopharmaceutical advancements. Its mission centers around the development of innovative therapies for retinal diseases, highlighting its commitment to patient care and outcome improvement. Currently, they are heavily focused on ensuring that their groundbreaking work with LYTENAVA™ can be translated into real-world treatment options.
Inquiries for Investors
If you have questions about their latest projects or would like to engage with the team at Outlook Therapeutics, you can reach out to:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
Email: OTLK@jtcir.com
Frequently Asked Questions
What is ONS-5010?
ONS-5010 is an investigational ophthalmic formulation of bevacizumab aimed at treating wet age-related macular degeneration.
What does NORSE EIGHT trial entail?
The NORSE EIGHT trial assesses the safety and efficacy of ONS-5010 in patients with wet AMD.
When is the expected launch for LYTENAVA™?
LYTENAVA™ is expected to launch in the EU and UK in the first half of calendar 2025.
What sets LYTENAVA™ apart?
It is the first authorized ophthalmic formulation of bevacizumab for treating retina disorders, delivering a new solution for patients.
How can investors find more information?
Investors can inquire directly by contacting Jenene Thomas at JTC Team, LLC.
